Organization
TapImmune, Inc.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
TapImmune, Inc.
... TapImmune Inc.(NASDAQ: TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian ...
... TapImmune Inc.(NASDAQ: TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian ...
... clinical study of TPIV2002017: Complete FDA filings required to initiate studies with TPIV 110 for treating HER2/neu+ breast cancer1H 2018: Report interim immune response data ...
... TapImmune Inc.(NASDAQ: TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian ...
... TapImmune Inc.(NASDAQ: TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian ...
... Spotlight on Innovation session featured four companies that have achieved major milestones:Intezyne Technologies(Tampa),Lakewood-Amedex(Sarasota),TapImmune(Jacksonville), andAltor BioScience(Miramar). BioFlorida also recognized individuals and organizations for their outstanding achievements ...
... TapImmune Inc.(NASDAQ: TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian ...
... TapImmune Inc.(NASDAQ: TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian ...
... dude pecking on a laptop. He walked up and introduced himself to Futura, a producer from France who had worked with Trey Songz, Kylie Minogue, ...
... responsible for the commercial strategy of such assets. Release > Immuno-oncology company TapImmune named Peter Hoang as president and CEO. He was most recently SVP ...
... TapImmune, Inc.(NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of immunotherapies targeting ...
... consultant at Garett Creative says using it makes you look "lazy." 2. Futura If you like a san serif typeface, one that doesn't have small ...
... Clinical Developments: Achieved 50% enrollment in ongoing Phase 2 dosing study of TPIV 200 for treating triple-negative breast cancer (TNBC)Completed $6.8 million financing; combination of ...
... TapImmune, Inc.(NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of immunotherapies targeting ...
... TapImmune, Inc.(NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of immunotherapies targeting ...
... a new option for women with bleak diagnoses. Below, Dr. Glynn Wilson, TapImmune's chairman and CEO, discusses the treatment. How does TapImmune differ from existing ...
... TapImmune, Inc.(NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of immunotherapies targeting ...
... TapImmune, Inc.(NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of immunotherapies targeting ...
... TapImmune Inc. (Nasdaq Capital Market: TPIV), a clinical-stage immuno-oncology company specializing in the development of ...
... TapImmune, Inc.(NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of immunotherapies targeting ...
... Clinical DevelopmentContinued advancing multiple Phase 2 clinical studies of lead vaccine candidate TPIV 200 in ovarian and triple-negative breast cancersProgressed preclinical development of proprietary PolyStart(TM) ...
Want to see the full history of news or view news on a particular date? Upgrade to RelSci Professional now!
Start My Free Trial ➤